Friday, 16 October 2026European Markets

PETRONOR E&P Stock 17.64% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with PETRONOR E&P (PNOR.OL) jumping 17.64% to kr8.15 on Wednesday while Oslo Børs Benchmark Index_GI rose 1.06% to kr1,198.67.

PETRONOR E&P's last close was kr6.93, 44.43% below its 52-week high of kr12.47.

About PETRONOR E&P

PetroNor E&P ASA operates as an independent oil and gas exploration and production company in West Africa. It holds exploration and production assets in offshore West Africa countries, which includes the PNGF Sud licenses in Congo Brazzaville, the A4 license in The Gambia, the Sinapa (Block 2) and Esperança (Blocks 4A and 5A) licenses in Guinea-Bissau, the Rufisque Offshore Profond and Senegal Offshore Sud Profond in Senegal, and OML-113 in Nigeria. The company was founded in 2017 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PETRONOR E&P has a trailing twelve months EPS of kr2.1.

PE Ratio

PETRONOR E&P has a trailing twelve months price to earnings ratio of 3.88. Meaning, the purchaser of the share is investing kr3.88 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 39.01%.

Volatility

PETRONOR E&P's last week, last month's, and last quarter's current intraday variation average was a negative 0.61%, a negative 0.19%, and a positive 1.74%.

PETRONOR E&P's highest amplitude of average volatility was 0.83% (last week), 1.41% (last month), and 1.74% (last quarter).

Yearly Top and Bottom Value

PETRONOR E&P's stock is valued at kr8.15 at 22:36 EST, way under its 52-week high of kr12.47 and way higher than its 52-week low of kr0.72.

More news about PETRONOR E&P (PNOR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com